TREOCAPA:通过亚美诺芬统计分析计划对早产婴儿的动脉管道进行预防性治疗,用于随机的III期组顺序试验
Moreno Ursino1,2,3, Corinne Alberti1, Gilles Cambonie4
1Université Paris Cité, AP-HP, Unité d'épidémiologie clinique, Inserm, CIC-EC 1426, Paris, France.
Trials
|February 13, 2025
概括
在极度早产婴儿的预防性乙氨基并没有显著改善没有严重发病的生存率. 需要进一步的研究来了解其对导管动脉关闭和新生儿结局的影响.
科学领域:
- 新生儿医学 新生儿医学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 在极度早产的婴儿中,持续的专利动脉管 (PDA) 管理仍然是一个挑战.
- 目前用于PDA的治疗策略并没有改善新生儿的结局.
- 乙氨基正在被研究为潜在的更安全的替代PDA治疗.
研究的目的:
- 为了确定预防性乙氨基是否会增加早产婴儿在36周的月经后没有严重发病的存活率.
- 评估乙氨基在减少BPD,NEC和IVH等严重疾病的疗效.
主要方法:
- 三期TREOCAPA:一个随机的,多中心的,双盲的,安慰剂控制的试验.
- 803名早产婴儿 (23-28周妊娠年龄) 被纳入.
- 婴儿根据妊娠年龄组接受特定的乙氨基剂量.
主要成果:
- 该研究的目标是检测在没有严重发病的情况下生存率增加10%.
- 严重的疾病包括严重的BPD,NEC,IVH或囊性白血病.
- 结果正在等待,并将向新生儿科学界传播.
结论:
- 该研究的结果将为早产婴儿PDA的管理提供信息.
- 结果将表明乙氨基是否有益,有害或对新生儿结局没有影响.
- 超声波数据可能会阐明通道动脉关闭在结果中的作用.
相关概念视频
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...